First-in-Class Oral IRF5 Degrader, KT-579, Demonstrates Significant Activity Alone or in the Presence of Background Therapies in Preclinical Lupus Models

November 10, 2026

First-in-Class Oral IRF5 Degrader, KT-579, Demonstrates Significant Activity Alone or in the Presence of Background Therapies in Preclinical Lupus Models

American College of Rheumatology (ACR) 2026

Erik Corcoran, Emily Lurier, Jordan Leedberg, Yi Zhang, Chris Ho, Dapeng Chen, Revonda Mehovic, Rahul Karnik, Sarah Martinez, Susanne Breitkopf, Veronica Campbell

Area of Focus
Immunology
Programs
IRF5 (KT-579)
Indications
Lupus
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link